BioSpace News Archive

Rain Therapeutics Inc. (NasdaqGS: RAIN), (Rain) today announced an oral presentation at the Connective Tissue Oncology Society (CTOS) Annual Meeting taking place on November 16-19, 2022 in Vancouver, BC, Canada.

Avenge Bio, Inc. (“Avenge” or the “Company”), a biotechnology company developing the LOCOcyte™ Immunotherapy platform for the precision administration of potent immune effector molecules to treat solid tumors, today announced Michael Heffernan, Founder and Chief Executive Officer, will present at the Piper Sandler 34th Annual Healthcare Conference in New York.

SafeSource Direct, LLC, the maker of high-quality, American-made personal protective equipment (PPE), announced today that its chemo-rated nitrile exam gloves have received FDA 510(k) clearance.

Beyond Air, Inc. including serious lung infections and pulmonary hypertension, and, through its affiliate Beyond Cancer, Ltd., ultra-high concentration nitric oxide for the treatment of solid tumors, announced that Steve Lisi, Chairman and CEO of Beyond Air, will be presenting a corporate overview and participating in 1x1 meetings at the Piper 34th Annual Healthcare Conference being held November 29 – December 1, 2022 in New York, NY.

Element Materials Technology (Element), a leading global Testing, Inspection and Certification (TIC) company, today unveiled one of the first and largest post-pandemic, commercial bioaerosol testing facilities.

Annexon, Inc. announced that it has granted an equity inducement award to a new non-executive employee under the terms of the 2022 Employment Inducement Award Plan.

AngioDynamics, Inc. announced that Jim Clemmer, President and Chief Executive Officer, and Stephen Trowbridge, Executive Vice President and Chief Financial Officer, will present at the Piper Sandler 34th Annual Healthcare Conference at 10:10 a.m. ET on Wednesday, November 30, 2022.

GENFIT announced the highlights from its Pipeline Day events reviewing the Company’s clinical progress and recent strategic updates.

Centene Corporation announced that it has signed a definitive agreement to sell Magellan Specialty Health to Evolent Health, Inc.

GRAIL, LLC, a healthcare company whose mission is to detect cancer early when it can be cured, today announced findings from a fundamental substudy of the Circulating Cell-free Genome Atlas (CCGA; NCT02889978) study, demonstrating that methylation had the most promising combination of cancer detection and prediction of cancer signal origin when compared with other evaluated approaches.